|
1,976
|
| 15479 |
ACE2
|
|
decreases_quantity of
|
Glucose
|
in blood; after fasting
|
| 15480 |
ACE2
|
|
increases_activity of
|
improved glucose tolerance
|
intraperitoneal
|
| 15481 |
ACE2
|
|
increases_quantity of
|
Insulin
|
in pancreas, in pancreatic islets
|
| 15482 |
ACE2
|
|
affects_activity of
|
type B pancreatic cell proliferation
|
in pancreas, in pancreatic islets
|
| 15483 |
ACE2
|
|
affects_activity of
|
type B pancreatic cell apoptotic process
|
in pancreas, in pancreatic islets
|
| 15484 |
ACE2
|
NOT |
affects_activity of
|
increased insulin sensitivity
|
|
| 15485 |
MAS1
|
|
affects_activity of
|
ACE2
|
|
| 15486 |
ACE2
|
|
affects_activity of
|
Diabetes mellitus, type II
|
|
|
20660625
|
Diabetes mellitus, type II
Insulin resistance
|
|
8,605
|
| 88900 |
ACE2
|
|
affects_quantity of
|
Tryptophan
|
|
| 88903 |
ACE2
|
|
decreases_activity of
|
abnormal gut flora balance
|
|
|
28069752
|
Gastrointestinal
Metabolic
|
|
9,687
|
| 102338 |
ACE2
|
|
increases_quantity of
|
Alamandine
|
|
| 102339 |
ACE2
|
|
decreases_quantity of
|
Angiotensin A
|
|
|
23446738
|
Cardiovascular disease
|
|
11,676
|
| 116034 |
ACE2
|
|
increases_activity of
|
viral entry into host cell
|
by functioning as receptor for the virus surface protein spike SARS-S
|
| 116055 |
TMPRSS2
|
|
affects_activity of
|
ACE2
|
via proteolytic processing to improve SARS-S-driven transduction
|
| 116056 |
TMPRSS11D
|
|
affects_activity of
|
ACE2
|
via proteolytic processing to improve SARS-S-driven transduction
|
| 116057 |
HPN
|
|
affects_activity of
|
ACE2
|
via proteolytic processing
|
| 117128 |
SARS-CoV S protein
|
|
interacts (colocalizes) with
|
ACE2
|
|
| 117211 |
ADAM17
|
|
decreases_quantity of
|
ACE2
|
via proteolytic processing
|
| 119246 |
ACE2
|
|
increases_quantity of
|
ACE2, soluble
|
via proteolytic activity of ADAM17
|
|
24227843
|
Immunological
SARS-CoV infection
|
|
11,680
|
| 116080 |
ACE2
|
|
decreases_activity of
|
response to endoplasmic reticulum stress
|
decreasing ER stress
via activation of ACE2
|
| 116081 |
ACE2
|
|
increases_activity of
|
lipid metabolic process
|
in mouse skeletal muscle in vivo and in vitro
|
| 116082 |
ACE2
|
|
increases_activity of
|
IKBKB/NFKB1/IRS1 signaling
|
in mouse skeletal muscle in vivo and in vitro; improving the lipid metabolism
|
| 116085 |
ACE2
|
|
increases_activity of
|
mitochondrion
|
ameliorating mitochondrial function
via activation of ACE2
|
| 116086 |
ACE2
|
|
decreases_quantity of
|
Triacylglycerol
|
in db/db mice; slightly reducing TG content via activation of ACE2
|
| 116087 |
ACE2
|
|
decreases_expression of
|
lipogenic proteins
|
in db/db mice; down-regulated expression of skeletal muscle lipogenic proteins via activation of ACE2
|
| 116098 |
ACE2 KO mouse
|
|
decreases_expression of
|
ACE2
|
in the skeletal muscle of the ACE2 KO mice; concerning ACE2 mRNA content
|
| 116107 |
ACE2
|
|
increases_expression of
|
PPARA
|
in ACE2-overexpressing C2C12 cells; concerning PPARA mRNA; ACE2 has also been proved to be overexpressed after the adenoviruses infect
|
| 116108 |
ACE2
|
|
increases_expression of
|
PPARG
|
in ACE2-overexpressing C2C12 cells; concerning PPARG mRNA; ACE2 has also been proved to be overexpressed after the adenoviruses infect
|
| 116109 |
ACE2
|
|
increases_expression of
|
CPT1A
|
in ACE2-overexpressing C2C12 cells; concerning CPT1A mRNA; ACE2 has also been proved to be overexpressed after the adenoviruses infect
|
| 116110 |
ACE2
|
|
increases_activity of
|
fatty acid oxidation
|
in ACE2-overexpressing C2C12 cells
|
| 116113 |
ACE2
|
|
increases_activity of
|
endoplasmic reticulum
|
playing a notable role on intramuscular fat regulation by improving endoplasmic reticulum and mitochondrial function
|
| 116114 |
ACE2
|
|
decreases_activity of
|
response to endoplasmic reticulum stress
|
in ACE2-overexpressing C2C12 cells
|
| 116115 |
ACE2
|
|
increases_activity of
|
mitochondrion
|
playing a notable role on intramuscular fat regulation by improving endoplasmic reticulum and mitochondrial function
|
| 116142 |
ACE2
|
|
decreases_quantity of
|
ACACA
|
in ACE2-overexpressing db/db mice
|
| 116143 |
ACE2
|
|
decreases_quantity of
|
SREBF1
|
in ACE2-overexpressing db/db mice
|
| 116929 |
ACE2
|
|
decreases_activity of
|
abnormal mitochondrial physiology
|
reasoned via ACE2 KO mice in skeletal muscles
|
| 120293 |
ACE2
|
|
decreases_quantity of
|
HSPA5
|
in the skeletal muscle of ACE2 KO mice; GRP78 protein was up-regulated
|
|
31775868
|
Metabolic
Muscular
|
|
11,681
|
| 116054 |
ACE2
|
|
increases_activity of
|
insulin secretion involved in cellular response to glucose stimulus
|
the presence of H2O2 in INS-1 cells; ACE2 over-expression restored glucose-stimulated insulin secretion
|
| 116144 |
ACE2
|
|
increases_expression of
|
mitochondria-related genes
|
in INS-1 cells; when ACE2 is overexpressed
|
| 116147 |
ACE2
|
|
increases_activity of
|
increased intracellular calcium ion level
|
in islets from db/db mice; when ACE2 is overexpressed, via increased intracellular calcium influx
|
| 116149 |
ACE2
|
|
increases_activity of
|
mitochondrial oxidation
|
in db/db mouse islets; when ACE2 is overexpressed, causing an increase in GSIS
|
| 116151 |
ACE2
|
|
affects_activity of
|
mitochondrial metabolism
|
increasing intracellular calcium influx and improving insulin secretion in pancreatic beta-cells
|
| 116221 |
ACE2
|
|
increases_activity of
|
positive regulation of mitochondrial membrane potential
|
the presence of H2O2 in INS-1 cells; ACE2 over-expression restored mitochondrial membrane potential (MMP)
|
| 116248 |
ACE2
|
|
decreases_activity of
|
abnormal mitochondrial physiology
|
in islets from db/db mice; when ACE2 is overexpressed, restoring impaired mitochondrial oxidation
|
| 116273 |
ACE2
|
|
increases_expression of
|
ATP6V1C2
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116280 |
ACE2
|
|
increases_expression of
|
COX6C
|
in INS-1 cells treated with ACE2 plasmid; also concerning mRNA, when ACE2 is overexpressed
|
| 116282 |
ACE2
|
|
increases_expression of
|
NDUFA2
|
in INS-1 cells treated with ACE2 plasmid; also concerning mRNA, when ACE2 is overexpressed
|
| 116283 |
ACE2
|
|
increases_expression of
|
ATP6V1E2
|
in INS-1 cells treated with ACE2 plasmid; also concerning mRNA, when ACE2 is overexpressed
|
| 116284 |
ACE2
|
|
increases_expression of
|
UQCRH
|
in INS-1 cells treated with ACE2 plasmid; but not concerning the mRNA, when ACE2 is overexpressed
|
| 116286 |
ACE2
|
|
increases_expression of
|
ATP5MC3
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116287 |
ACE2
|
|
increases_expression of
|
COX6A1
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116288 |
ACE2
|
|
increases_expression of
|
ATP6V1G3
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116289 |
ACE2
|
|
increases_expression of
|
COX7B
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116295 |
ACE2
|
|
increases_expression of
|
COX4I1
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116296 |
ACE2
|
|
increases_expression of
|
LDHA
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116298 |
ACE2
|
|
increases_expression of
|
ATP5F1A
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116299 |
ACE2
|
|
increases_expression of
|
ATP5F1B
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116301 |
ACE2
|
|
increases_expression of
|
COX5B
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116303 |
ACE2
|
|
increases_expression of
|
NDUFS3
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116306 |
ACE2
|
|
increases_expression of
|
SLC25A10
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116308 |
ACE2
|
|
increases_expression of
|
B2M
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116309 |
ACE2
|
|
increases_expression of
|
ATP5MC2
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116311 |
ACE2
|
|
increases_expression of
|
NDUFA7
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116312 |
ACE2
|
|
increases_expression of
|
NDUFB3
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116313 |
ACE2
|
|
increases_expression of
|
NDUFV2
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116314 |
ACE2
|
|
increases_expression of
|
COX8A
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116317 |
ACE2
|
|
increases_expression of
|
ATP5ME
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116320 |
ACE2
|
|
increases_expression of
|
NDUFB6
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116321 |
ACE2
|
|
increases_expression of
|
COX7A2
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116322 |
ACE2
|
|
increases_expression of
|
ATP5PF
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116325 |
ACE2
|
|
increases_expression of
|
NDUFS5
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116326 |
ACE2
|
|
increases_expression of
|
ATP4A
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116327 |
ACE2
|
|
increases_expression of
|
NDUFA5
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116328 |
ACE2
|
|
increases_expression of
|
NDUFB7
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116330 |
ACE2
|
|
increases_expression of
|
COX5A
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116332 |
ACE2
|
|
increases_expression of
|
ATP6V0A2
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116334 |
ACE2
|
|
decreases_expression of
|
SDHC
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116336 |
ACE2
|
|
decreases_expression of
|
UQCRC1
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116337 |
ACE2
|
|
decreases_expression of
|
NNT
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116338 |
ACE2
|
|
decreases_expression of
|
PPA1
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116339 |
ACE2
|
|
decreases_expression of
|
NDUFV1
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116340 |
ACE2
|
|
decreases_expression of
|
UQCRFS1
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116342 |
ACE2
|
|
decreases_expression of
|
NDUFS1
|
in INS-1 cells treated with ACE2 plasmid; when ACE2 is overexpressed
|
| 116344 |
ACE2
|
|
decreases_activity of
|
mitochondrial depolarization
|
in INS-1 cells
|
| 116349 |
ACE2
|
|
increases_activity of
|
insulin secretion
|
in pancreatic beta-cells
|
|
29128354
|
Metabolic
Diabetes mellitus
|
|
11,684
|
| 116062 |
sex
|
|
affects_activity of
|
ACE2
|
in cardiac tissue
|
| 116065 |
Estradiol
|
|
decreases_activity of
|
ACE2
|
in cardiac tissue
|
| 116066 |
Testosterone
|
|
increases_activity of
|
ACE2
|
in cardiac tissue
|
| 116069 |
sex, female
|
|
decreases_activity of
|
ACE2
|
in cardiac tissue; compared to male
|
| 116070 |
sex, male
|
|
increases_activity of
|
ACE2
|
in cardiac tissue; compared to female
|
|
|
Cardiovascular disease
COVID-19
|
|
11,710
|
| 116266 |
ACE2
|
|
affects_activity of
|
heart left ventricle hypertrophy
|
|
| 116269 |
ACE2
|
|
affects_activity of
|
Diabetes mellitus, type II
|
|
|
30227878
|
Diabetes mellitus, type II
Insulin resistance
Cardiovascular disease
|
|
11,717
|
| 116331 |
ACE2
|
|
is_expressed_in
|
pancreatic islet
|
|
| 116346 |
ACE2
|
|
decreases_quantity of
|
Angiotensin II
|
|
| 116348 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116381 |
ACE2
|
|
affects_activity of
|
increased pancreatic islet vascularization
|
|
| 116382 |
ACE2
|
|
increases_activity of
|
insulin secretion involved in cellular response to glucose stimulus
|
|
| 116389 |
ACE2
|
|
affects_activity of
|
Diabetes mellitus, type II
|
|
| 116390 |
ACE2
|
|
affects_activity of
|
type B pancreatic cell proliferation
|
|
| 116395 |
ACE2
|
|
affects_expression of
|
AGTR1
|
in pancreas
|
| 116396 |
ACE2
|
|
affects_activity of
|
response to oxidative stress
|
in pancreas
|
| 116407 |
ACE inhibitor
|
|
increases_activity of
|
ACE2
|
in pancreatic islets
|
| 116408 |
ACE2
|
|
increases_activity of
|
mitochondrion
|
in pancreatic beta cells
|
|
30404071
|
Diabetes mellitus, type II
Insulin resistance
|
|
11,748
|
| 116293 |
SARS-CoV-2
|
|
interacts (colocalizes) with
|
ACE2
|
|
| 116365 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-9)
|
|
| 116366 |
ACE2
|
|
decreases_quantity of
|
Angiotensin I
|
|
| 116369 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116370 |
ACE2
|
|
decreases_quantity of
|
Angiotensin II
|
|
| 116388 |
ADAM17
|
|
affects_activity of
|
ACE2
|
via proteolysis
|
| 116406 |
SARS virus
|
|
decreases_activity of
|
ACE2
|
by binding to ACE2
|
| 116440 |
SARS virus
|
|
decreases_expression of
|
ACE2
|
|
|
32333398
|
COVID-19
|
|
11,756
|
| 116443 |
ACE2
|
|
is_expressed_in
|
cardiac muscle fiber
|
|
| 116444 |
ACE2
|
|
is_expressed_in
|
alveolar cell type II
|
|
| 116635 |
ACE2
|
|
decreases_activity of
|
lung injury
|
|
|
32333398
|
COVID-19
|
|
11,758
|
| 116457 |
TGFB1
|
|
decreases_expression of
|
ACE2
|
in A549 cells; via inhibiting SIRT1 expression
|
| 116458 |
TGFB1
|
|
decreases_quantity of
|
ACE2
|
in A549 cells; via inhibiting SIRT1 expression
|
| 116460 |
SIRT1
|
|
increases_expression of
|
ACE2
|
in A549 cells
|
|
31387171
|
Pulmonary fibrosis, idiopathic
|
|
11,776
|
| 116580 |
ACE2
|
|
decreases_quantity of
|
Angiotensin I
|
|
| 116581 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-9)
|
|
| 116588 |
ACE2
|
|
decreases_quantity of
|
Angiotensin II
|
|
| 116589 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116609 |
ACE2
|
|
decreases_activity of
|
Nephropathy, diabetic
|
|
| 116613 |
ACE2
|
|
affects_activity of
|
Cardiomyopathy, diabetic
|
|
| 116626 |
ACE2
|
|
affects_activity of
|
insulin secretion
|
in pancreas
|
|
23463883
|
Diabetes mellitus, type II
Insulin resistance
Cardiovascular disease
|
|
11,777
|
| 116541 |
embryo development
|
|
affects_expression of
|
ACE2
|
|
|
26029927
|
Diabetes mellitus, type II
Insulin resistance
|
|
11,778
|
| 116650 |
SARS-CoV S protein
|
|
interacts (colocalizes) with
|
ACE2
|
|
| 116651 |
SARS-CoV-2 S protein
|
|
interacts (colocalizes) with
|
ACE2
|
|
| 116653 |
ACE inhibitor
|
|
increases_quantity of
|
ACE2
|
|
| 116654 |
Angiotensin II type 1 receptor blocker
|
|
increases_quantity of
|
ACE2
|
|
| 116655 |
SARS-CoV
|
|
decreases_expression of
|
ACE2
|
|
| 116656 |
Ibuprofen
|
|
increases_quantity of
|
ACE2
|
|
| 116657 |
Thiazolidinedione
|
|
increases_quantity of
|
ACE2
|
|
|
32278764
|
Diabetes mellitus, type II
Insulin resistance
COVID-19
|
|
11,821
|
| 116756 |
SARS-CoV-2
|
|
interacts (colocalizes) with
|
ACE2
|
|
| 116757 |
ACE2
|
|
decreases_quantity of
|
Angiotensin II
|
|
| 116758 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116761 |
SARS-CoV S protein
|
|
interacts (colocalizes) with
|
ACE2
|
|
| 116763 |
ACE2
|
|
affects_activity of
|
SARS-CoV infection
|
|
| 116764 |
SARS-CoV infection
|
|
decreases_quantity of
|
ACE2
|
in lung
|
| 116768 |
Influenza A H5N1 infection
|
|
decreases_expression of
|
ACE2
|
in lung
|
| 116771 |
Angiotensin II type 1 receptor blocker
|
|
increases_quantity of
|
ACE2
|
|
| 116774 |
ACE inhibitor
|
NOT |
decreases_activity of
|
ACE2
|
|
|
32341442
|
COVID-19
|
|
11,822
|
| 116784 |
ACE2
|
|
decreases_quantity of
|
Angiotensin II
|
|
| 116790 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116793 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-9)
|
|
| 116794 |
ACE2
|
|
decreases_quantity of
|
Angiotensin I
|
|
|
32336612
|
COVID-19
|
|
11,823
|
| 116801 |
Cl-
|
|
increases_activity of
|
ACE2
|
|
| 116803 |
Fluoride
|
|
increases_activity of
|
ACE2
|
|
| 116804 |
ACE2
|
|
decreases_quantity of
|
Angiotensin II
|
|
| 116809 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116812 |
ACE2
|
|
decreases_quantity of
|
Apelin-13
|
|
| 116814 |
ACE2
|
|
decreases_quantity of
|
Apelin-36
|
|
| 116846 |
ACE2
|
|
decreases_quantity of
|
Dynorphin A (1-13)
|
|
| 116849 |
ACE2
|
|
increases_quantity of
|
Dynorphin A (1-12)
|
|
| 116852 |
ACE2
|
|
decreases_quantity of
|
des-Arg9-bradykinin
|
|
| 116855 |
ACE2
|
|
decreases_quantity of
|
Neurotensin 1-8
|
|
| 116859 |
ACE2
|
|
decreases_quantity of
|
Angiotensin I
|
with low activity as for angiotensin II
|
|
11815627
|
Metabolic
|
|
11,826
|
| 116858 |
SARS-CoV-2
|
|
interacts (colocalizes) with
|
ACE2
|
|
|
32015507
|
COVID-19
|
|
11,827
|
| 116824 |
SARS-CoV-2 S protein
|
|
interacts (colocalizes) with
|
ACE2
|
|
|
32142651
|
COVID-19
|
|
11,828
|
| 116825 |
SARS-CoV-2 S protein
|
|
interacts (colocalizes) with
|
ACE2
|
|
|
32155444
|
COVID-19
|
|
11,829
|
| 116826 |
SARS-CoV S protein
|
|
interacts (colocalizes) with
|
ACE2
|
|
|
14647384
|
SARS-CoV infection
|
|
11,830
|
| 116827 |
SARS-CoV
|
|
interacts (colocalizes) with
|
ACE2
|
|
| 116880 |
SARS-CoV infection
|
|
decreases_expression of
|
ACE2
|
|
| 116881 |
SARS-CoV S protein
|
|
decreases_expression of
|
ACE2
|
|
| 119082 |
SARS-CoV infection
|
|
decreases_quantity of
|
ACE2
|
in the lung
|
|
16007097
|
SARS-CoV infection
|
|
11,837
|
| 116869 |
ACE2
|
|
decreases_quantity of
|
Angiotensin I
|
|
| 116870 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-9)
|
|
|
10969042
|
Endocrine
|
|
11,841
|
| 116900 |
ACE2
|
|
decreases_activity of
|
renin-angiotensin system
|
ACE2 is a negative regulator of the renin-angiotensin system (RAS)
|
| 116901 |
ACE2
|
|
is_expressed_in
|
lung
|
|
| 116902 |
ACE2
|
|
increases_activity of
|
SARS-CoV-2 infection
|
as the SARS-CoV-2 receptor provides a critical link between immunity, inflammation, ACE2, and cardiovascular disease
|
| 116903 |
SARS-CoV-2 infection
|
|
decreases_activity of
|
ACE2
|
driven by endocytosis and activation of proteolytic cleavage and processing
|
| 116904 |
ACE2
|
|
affects_activity of
|
gut dysbiosis
|
|
| 116905 |
ACE2
|
|
increases_activity of
|
viral entry into host cell
|
at the epithelial surface
|
| 116906 |
ACE2
|
|
decreases_activity of
|
SARS-induced tissue injuries
|
|
| 116907 |
ACE2
|
|
increases_activity of
|
amino acid transport
|
|
| 116908 |
ACE2
|
|
interacts (colocalizes) with
|
SARS-CoV-2
|
ACE2 is a SARS-CoV-2 receptor
|
| 116909 |
ACE2
|
|
interacts (colocalizes) with
|
SARS-CoV
|
ACE2 is a SARS-CoV receptor
|
| 116910 |
ACE2
|
|
is_expressed_in
|
kidney
|
|
| 116911 |
ACE2
|
|
is_expressed_in
|
gut
|
|
| 116912 |
ACE2
|
|
is_expressed_in
|
cardiovascular system
|
|
| 116913 |
ACE2
|
|
is_expressed_in
|
central nervous system
|
|
| 116914 |
ACE2
|
|
is_expressed_in
|
adipose tissue
|
|
| 116916 |
ACE2
|
|
affects_activity of
|
regulation of vascular permeability
|
|
| 116918 |
ADAM17
|
|
increases_processing of
|
ACE2
|
via proteolytic cleavage
|
| 116922 |
endocytosis
|
|
decreases_activity of
|
ACE2
|
concerning ACE2-mediated cardiovascular protection
|
| 116955 |
ACE2
|
|
increases_activity of
|
cardiovascular protection
|
this is lost following endocytosis of the enzyme
|
| 116962 |
SARS-CoV S protein
|
|
decreases_expression of
|
ACE2
|
concerning downregulation of surface ACE2 expression
|
| 116963 |
SARS-CoV-2 S protein
|
|
decreases_expression of
|
ACE2
|
concerning downregulation of surface ACE2 expression
|
|
32264791
|
COVID-19
SARS-CoV infection
|
|
11,842
|
| 116928 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-7)
|
in kidney ; at neutral to basic pH
|
|
23392115
|
Endocrine
|
|
11,846
|
| 121044 |
ACE2
|
|
interacts (colocalizes) with
|
SARS-CoV S protein
|
|
| 121117 |
ACE2
|
|
increases_activity of
|
SARS-CoV infection
|
|
| 121118 |
SARS-CoV infection
|
|
decreases_expression of
|
ACE2
|
|
| 121119 |
SARS-CoV S protein
|
|
decreases_expression of
|
ACE2
|
|
|
19411314
|
SARS-CoV infection
|
|
11,847
|
| 133580 |
SARS-CoV S protein
|
|
decreases_quantity of
|
ACE2
|
in the cytoplasm
|
|
18490652
|
SARS-CoV infection
|
|
11,848
|
| 116997 |
SARS-CoV S protein
|
|
decreases_quantity of
|
ACE2
|
|
|
19864379
|
SARS-CoV infection
|
|
11,849
|
| 116999 |
Calmodulin
|
|
interacts (colocalizes) with
|
ACE2
|
decreased by calmodulin inhibitors
|
|
18070603
|
SARS-CoV infection
|
CIDeRplus